Condition 1: Coronavirus (COVID-19)-induced pneumonia. Condition 2: Coronavirus (COVID-19)-induced pneumonia. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Twenty patients with Coronavirus (COVID-19)-induced pneumonia addition to standard regimen of covid-19? will receive Fingolimod for 1 day (50 mg one time). Interve
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Moderate to severe 2019-nCoV-infected 18 Years to 80 Years Patients or authorized family members volunteered to participate in this study and signed informed consent Both genders
Exclusion criteria
Exclusion criteria: Patient with elevated liver enzymes (3 times) Patients who are participating in other drug clinical trials Patients with active pulmonary tuberculosis Patients with definite bacterial and fungal infections Pregnant or lactating women Patient with active thrombotic event
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of the symptoms of lung, pulmonary infiltrates. Timepoint: At baseline (before intervention) and 2 day after drug administration. Method of measurement: Lung CT scan.;Decreased hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: counting the hospitalization days.;Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: observation.;Need for intubation. Timepoint: period of hospitalization. Method of measurement: observation or reading of hospitalized documents. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Khalil Ansarin
Tabriz University of Medical Sciences
Outcome results
None listed